COVID-19 Antigens

  • Use Sengenics’ correctly folded spike, nucleocapsid or envelope COVID-19 antigens for production of a high-affinity vaccine

  • Development of an antigen-based COVID-19 sero-diagnostic test for patient screening or immunosurveillance purposes

  • Fundamental research: characterisation of full-length, correctly folded and functional SARS-CoV-2 antigens

ImmuSAFE COVID+ Biochip Test

  • World’s first high-throughput, multi-domain COVID-19 antibody test

  • Population antibody profiling for seroprevalence research

  • Determine the protective quality and quantity of antibodies produced

  • Enable quantitative assessment of antigen-specific response by individuals in vaccine trials

IMMUNOME Protein Array

  • High-throughput platform for autoantibody biomarker discovery and protein-protein interactions
  • Exploratory arrays capable of screening over 1600 proteins in quadruplicate
  • Picogram level sensitivity – fully quantitative assay
  • Exceptional consistency and batch-to-batch reproducibility

CTA Array

  • High-throughput quantification of autoantibodies to Cancer-Testis (CT) antigens
  • Patient stratification in checkpoint inhibitor studies
  • Picogram level sensitivity – fully quantitative assay
  • Exceptional consistency and batch-to-batch reproducibility

Custom Arrays

  • Parallel screening of multiple samples on one slide
  • Proteins can be selected from our existing library or can be custom made
  • Choose from 2, 4, 8 or 16-plex format
  • Bespoke content and project design service

OncoREX p53 Cancer Array

  • Cancer drug screening and discovery
  • Screen 100 mutant p53 protein array in one experiment
  • Same chip can also be used for aAb specificity and analysis
  • Protein spotted in triplicate


Resources to access our technology


Your technical questions – answered


One technology – endless possibilities

Sengenics - Functional Proteomics | Krex Technology | Protein Array Supplier

Sengenics is a functional proteomics company that leverages its patented KREX technology for production of full-length, correctly folded and functional proteins. The key application of KREX is the discovery of autoantibody biomarkers for two core medical use cases:  stratification of patients undergoing treatment with autoimmune or cancer drugs and identification of autoantibody biomarkers that may be used to diagnose cancer, autoimmune or neurodegenerative conditions. Some autoantibodies that are identified as diagnostic biomarkers may be protective and have potential in themselves as therapeutic biomolecules.

Find Us On:

© 2008 – 2021 Sengenics All rights reserved | Sengenics Corporation Pte Ltd. Registered in Singapore no. 201734100D | Sengenics UK Ltd. Registered in England and Wales No 11016361